Investigating the Impact of GLP-1 RA Therapy on Osteosarcopenia in Older Female Adults With Diabetes

Summary

The goal of this study is to learn how GLP-1 receptor agonist therapy affects muscle and bone health in older females over age 65 with type 2 diabetes. The main question it aims to answer is whether or not 6 months of GLP-1 RA therapy affects muscle strength. Participants will: * Receive GLP-1 RA therapy as part of their routine clinical care * Complete muscle strength assessments (hand grip strength, Timed Up and Go test) * Provide blood samples for bone turnover markers * Undergo bone mineral density testing

Eligibility

Inclusion Criteria:

* Postmenopausal women aged 65 years or older
* Has type 2 diabetes
* Body Mass Index (BMI) ≥27 kg/m² to max 40kg/m2 (inclusive)
* Hemoglobin A1c \>7% within 3 months of the first visit.
* Willingness and ability to comply with all study procedures, including fasting requirements for certain visits.
* No osteoporosis confirmed on DEXA scan within 12 months
* Able to provide informed consent and participate in all study assessments

Exclusion Criteria:

* Patients with type 1 diabetes mellitus or other types of diabetes that are not T2D
* eGFR \<30 ml/min in the last 3 months
* Patients with a history of treatment with anti-osteoporosis agents
* Documented primary or secondary osteoporosis on a DEXA scan within the last 12 months, or are on osteoporosis therapies
* Documented presence of prosthesis or devices in the spine or hip
* Previous fragility fracture
* Males
* Moderate to severe gastroesophageal reflux disease based on patient history.
* Inability to comply with the treatment protocol or to understand the consent form.
* Aspartate aminotransferase (AST) \> 3 times normal or alanine aminotransferase (ALT) \> 3 times the normal
* Subjects with uncontrolled thyroid or parathyroid disease that may influence the study results.
* Personal or family history of medullary thyroid carcinoma.
* Personal or family history of multiple endocrine neoplasia type 2 syndrome.
* Personal history of gastroparesis, celiac disease, hypogonadism, severe COPD, hypopituitarism, or Cushing's disease
* Personal history of severe diabetic retinopathy.
* Known serious hypersensitivity, including anaphylaxis and angioedema, to semaglutide or any of its excipients.
* Any of the following drugs or treatments were used within 6 months before screening: treated with GLP-1RA, GIP analogues, pioglitazones
* Concomitant treatment with GLP-1 receptor agonist therapy
* Long-term intravenous, oral, and intra-articular administration of high-dose corticosteroids within 2 months before screening (more than 7 days in a row)
* Use of weight control drugs or surgery that can lead to weight changes during the last 6 months before screening, or are currently in the weight loss plan and are not in the maintenance stage
* Incarcerated individuals

Conditions2

Interventions1

Locations1 site

Find trials near these locations

Related trials

• A Study of BGM0504 in Participants With Type 2 Diabetes in Indonesia — BrightGene Bio-Medical Technology Co., Ltd.
• A Study of the Effect of (S)-Pindolol Benzoate (ACM-001.1) on Lean Body Mass (LBM) in Obese Patents During (PROACT 1), and Post-semaglutide Therapy (PROACT 2) — Actimed Therapeutics Ltd
• COMMETS- Combination MCI Metabolic Syndrome — Rutgers, The State University of New Jersey
• Efficacy and Safety of Empagliflozin or Semaglutide in Overweight/Obese Patients With Type 1 Diabetes — Mostafa Bahaa
• GLP1-RAs Effects on Inflammatory and Endothelial Biomarkers in T2DM — Federico II University
• Multifactorial Intervention to Reduce Cardiovascular Disease in Type 1 Diabetes — Steno Diabetes Center Copenhagen
• Probiotic Intervention on Body Weight — Chinese Academy of Sciences
• Protein Supplementation Intervention on Body Weight — Chinese Academy of Sciences

Browse More Trials